Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Gorrod, Helen Bell
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. [electronic resource] - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 07 2019 - 772-776 p. digital
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1524-4733
10.1016/j.jval.2018.11.015 doi
Cladribine--administration & dosage
Confounding Factors, Epidemiologic
Disability Evaluation
Disease Progression
Drug Substitution
Humans
Immunosuppressive Agents--administration & dosage
Models, Statistical
Multiple Sclerosis, Relapsing-Remitting--diagnosis
Patient Dropouts
Time Factors
Treatment Outcome
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. [electronic resource] - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 07 2019 - 772-776 p. digital
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1524-4733
10.1016/j.jval.2018.11.015 doi
Cladribine--administration & dosage
Confounding Factors, Epidemiologic
Disability Evaluation
Disease Progression
Drug Substitution
Humans
Immunosuppressive Agents--administration & dosage
Models, Statistical
Multiple Sclerosis, Relapsing-Remitting--diagnosis
Patient Dropouts
Time Factors
Treatment Outcome